Safety Landscape of Therapeutic Nanozymes and Future Research Directions
Advanced Science · 2024-12 · 11 (46)
DOI: 10.1002/advs.202407816 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 24.10.2024. Verfasst von Nikolaos Tagaras und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Particles-Biology Interactions, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, 9014, Switzerland. Hauptthemen laut MEDLINE: Nanostructures. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 292 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Oxidative stress and inflammation are at the root of a multitude of diseases. Treatment of these conditions is often necessary but current standard therapies to fight excessive reactive oxygen species (ROS) and inflammation are often ineffective or complicated by substantial safety concerns. Nanozymes are emerging nanomaterials with intrinsic enzyme‐like properties that hold great promise for effective cancer treatment, bacterial elimination, and anti‐inflammatory/anti‐oxidant therapy. While there is rapid progress in tailoring their catalytic activities as evidenced by the recent integration of single‐atom catalysts (SACs) to create next‐generation nanozymes with superior activity, selectivity, and stability, a better understanding and tuning of their safety profile is imperative for successful clinical translation. This review outlines the current applied safety assessment approaches and provides a comprehensive summary of the safety knowledge of therapeutic nanozymes. Overall, nanozymes so far show good in vitro and in vivo biocompatibility despite considerable differences in their composition and enzymatic activities. However, current safety investigations mostly cover a limited set of basic toxicological endpoints, which do not allow for a thorough and deep assessment. Ultimately, remaining research gaps that should be carefully addressed in future studies are highlighted, to optimize the safety profile of therapeutic nanozymes early in their pre‐clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Particles-Biology Interactions, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, 9014, Switzerland.
- Department of Health Sciences and Technology, ETH Zurich, Zurich, 8093, Switzerland.
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, 310058, China.
- College of Chemical and Biological Engineering, MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, 3100…
ORCID-Profile: Nikolaos Tagaras, Shafaq Sahar, Weijun Tong, Zhengwei Mao, Tina Buerki-Thurnherr
Förderung
- National Natural Science Foundation of China
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Tagaras, N., Song, H., Sahar, S., Tong, W., Mao, Z., & Buerki-Thurnherr, T. (2024). Safety Landscape of Therapeutic Nanozymes and Future Research Directions. Advanced Science, 11(46). https://doi.org/10.1002/advs.202407816
Vancouver
Tagaras N, Song H, Sahar S, Tong W, Mao Z, Buerki-Thurnherr T. Safety Landscape of Therapeutic Nanozymes and Future Research Directions. Advanced Science. 2024;11(46). doi:10.1002/advs.202407816
BibTeX
@article{Tagaras2024,
author = {Tagaras, Nikolaos and Song, Haihan and Sahar, Shafaq and Tong, Weijun and Mao, Zhengwei and Buerki-Thurnherr, Tina},
title = {Safety Landscape of Therapeutic Nanozymes and Future Research Directions},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {46},
doi = {10.1002/advs.202407816}
}
EUVIMED